BRCA1 and ovarian cancer: In order to improve the quality of the available data, it is imperative that women with pathogenic variants in the BRCA1 or 2 gene are distinctly included in large registries, such as the HerediCaRe of the German Consortium for Hereditary Breast and Ovarian Cancer, in which all interventions should be recorded in detail, reliably, and prospectively.